EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy

Michael T Eadon iD, David W Hein iD, Michael A Andersen iD, Arlene B Chapman iD, Rhonda M Cooper-DeHoff iD, Zeruesenay Desta iD, Julio D Duarte iD, Amanda L Elchynski iD, Andrea Gaedigk iD, Seth E Karol iD, Nita A Limdi iD, Christelle Lteif iD und 7 weitere

Clinical Pharmacology & Therapeutics · 2025-12 · 118 (6) · 1430-1436

DOI: 10.1002/cpt.70071 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 19.09.2025. Verfasst von Michael T Eadon und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Hydralazine, Arylamine N-Acetyltransferase, Pharmacogenetics, Antihypertensive Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHGRI NIH HHS, NIGMS NIH HHS, National Institutes of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hydralazine is a vasodilator typically used in the treatment of resistant hypertension and heart failure. N‐acetyltransferase 2 (NAT2) catalyzes the metabolism of hydralazine into inactive metabolites. NAT2 poor metabolizers (historically referred to as “slow acetylators”) are predicted to have increased plasma hydralazine concentrations compared with NAT2 rapid and intermediate metabolizers (historically referred to as “rapid acetylators” and “intermediate acetylators,” respectively), which may lead to both increased clinical efficacy and adverse effects, including drug‐induced systemic lupus erythematosus. This guideline summarizes the evidence from the literature relevant to NAT2 /hydralazine and provides recommendations for hydralazine prescribing based on NAT2 genotype‐predicted acetylator phenotype (updates at www.cpicpgx.org ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydralazineArylamine N-AcetyltransferasePharmacogeneticsAntihypertensive AgentsVasodilator AgentsHumansGenotypePhenotypeHypertensionHeart Failure

Substanzen

HydralazineArylamine N-AcetyltransferaseNAT2 protein, humanAntihypertensive AgentsVasodilator Agents

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky, USA.
  • Department of Clinical Pharmacology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.
  • Department of Medicine, University of Chicago, Chicago, Illinois, USA.
  • Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, University of Florida College of Pharmacy, Gainesville, Florida, USA.
  • Department of Pharmacy, Arkansas Children's Hospital, Little Rock, Arkansas, USA.

ORCID-Profile: Michael T Eadon, David W Hein, Michael A Andersen, Arlene B Chapman, Rhonda M Cooper-DeHoff, Zeruesenay Desta, Julio D Duarte, Amanda L Elchynski, Andrea Gaedigk, Seth E Karol, Nita A Limdi, Christelle Lteif, Pablo Zubiaur, Michelle Whirl-Carrillo, Teri E Klein, Kelly E Caudle, Roseann S Donnelly, José A G Agúndez

Förderung

  • NHGRI NIH HHS
  • NIGMS NIH HHS
  • National Institutes of Health (NIH)
  • NIEHS NIH HHS
  • ALSAC
  • NCI NIH HHS
  • NCCIH NIH HHS
  • NIC

Zitieren

APA

Eadon, M. T., Hein, D. W., Andersen, M. A., Chapman, A. B., Cooper-DeHoff, R. M., Desta, Z., Duarte, J. D., Elchynski, A. L., Gaedigk, A., Karol, S. E., Limdi, N. A., Lteif, C., Sosinski, L., Zubiaur, P., Whirl-Carrillo, M., Klein, T. E., Caudle, K. E., Donnelly, R. S., & Agúndez, J. A. G. (2025). Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy. Clinical Pharmacology & Therapeutics, 118(6), 1430-1436. https://doi.org/10.1002/cpt.70071

Vancouver

Eadon MT, Hein DW, Andersen MA, Chapman AB, Cooper-DeHoff RM, Desta Z, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy. Clinical Pharmacology & Therapeutics. 2025;118(6):1430-1436. doi:10.1002/cpt.70071

BibTeX
@article{Eadon2025,
  author = {Eadon, Michael T and Hein, David W and Andersen, Michael A and Chapman, Arlene B and Cooper-DeHoff, Rhonda M and Desta, Zeruesenay and Duarte, Julio D and Elchynski, Amanda L and Gaedigk, Andrea and Karol, Seth E and Limdi, Nita A and Lteif, Christelle and Sosinski, Laura and Zubiaur, Pablo and Whirl-Carrillo, Michelle and Klein, Teri E and Caudle, Kelly E and Donnelly, Roseann S and Agúndez, José A G},
  title = {Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {118},
  number = {6},
  pages = {1430--1436},
  doi = {10.1002/cpt.70071}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche